Printer Friendly


 LA JOLLA, Calif., Oct. 20 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) announced today that it has received a notice of allowance from the European Patent Office of a European patent (no. 0469064) for a group of compounds related in activity to LIDAKOL(TM), the company's proprietary anti-viral and anti-inflammatory compound. This new patent, which will issue on Nov. 3, 1993, provides protection for a family of long chain alcohols distinct from LIDAKOL(TM) in structure when used in a systematic formulation for the treatment of viral and inflammatory disease in both humans and animals.
 David H. Katz, M.D., president and chief executive officer stated, "LIDAK has recognized the importance of having a strong patent position in bringing products to commercialization. We have devoted considerable effort to establishing the broadest possible patent position for LIDAKOL(TM) and all related chemical compounds in both the United States and Europe. By covering these related chemicals we have prevented their possible exploitation by others as potential competitive drugs."
 This represents the seventh patent issued to LIDAK covering LIDAKOL(TM) and related chemicals. In Sept. 1993, a European patent was issued covering the topical formulation of LIDAKOL(TM) as a treatment for viral and inflammatory diseases. Previously issued United States patents cover the use of LIDAKOL(TM) and related chemicals both topically and systemically as a treatment for viral and inflammatory diseases.
 "This new patent represents an important expansion of our proprietary position in Europe. Development of systemic formulations of LIDAKOL(TM) and related chemicals is important for achieving our long- term goal of maximizing the potential of this exciting new drug," said Dr. Katz.
 LIDAK's initial efforts focus on the development of LIDAKOL(TM) as a topical treatment for oral and genital herpes. The company recently announced the successful completion of a Phase II study of LIDAKOL(TM) as a treatment for herpes labialis (oral herpes) conducted in Europe by its European licensing partner Brocades Pharma, B.V. Two separate Phase II trials are ongoing in the United States. One trial, initiated in Nov., 1992, is testing LIDAKOL(TM) in patients with recurrent genital herpes. The other trial, which began in April, 1993, is testing the compound in patients with recurrent oral herpes. Development work on the systemic formulation of LIDAKOL(TM) is in late pre-clinical stage and the company expects to initiate formal pre-clinical toxicology testing of a systemic formulation during 1994.
 LIDAK Pharmaceuticals is developing therapeutic products against virally caused diseases, inflammatory disorders and cancer. The company's initial focus is on the commercialization of LIDAKOL(TM) as a treatment for herpes and other indications.
 The company is also developing its Large Multivalent Immunogen (LMI) technology for potential new therapies against cancer and viral disorders.
 -0- 10/20/93
 /CONTACT: Michael H. Lorber, vice president/CFO of LIDAK Pharmaceuticals, 619-558-0364, or Fern Lazar of Dewe Rogerson, Inc., 212-688-6840/

CO: LIDAK Pharmaceuticals ST: California IN: MTC SU:

TM -- NY008 -- 4322 10/20/93 07:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 20, 1993

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters